Managing invasive fungal infection in hematopoietic stem-cell transplantation.
Reduced intensity conditioning regimens and a wider range of donor sources, including cord blood, mean that more patients can be offered potentially curative allogeneic hematopoietic stem cell transplantation than ever before. Although these modalities aim to reduce procedure-related morbidity and mortality, their potential benefit may be overshadowed by a changing spectrum of problems related to the immunocompromised status of affected patients. Acute or chronic extensive graft-versus-host disease, which occasionally emerges in the late post-transplant period, and prolonged neutropenia due to delayed engraftment still carry a substantial risk of invasive fungal and other infections. As a result, advances in antifungal prophylaxis and pre-emptive treatment were widely reported at the 36th Annual Meeting of the European Group for Blood and Marrow Transplantation attended this year by approximately 3800 delegates.
Sinkó
János
J
St István & St László Hospital, Budapest, Hungary. janos.sinko@istvankorhaz.hu
Bryan
Jenny
J
D000293:Adolescent; D000328:Adult; D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D058365:Candidiasis, Invasive / Q000188:drug therapy / Q000382:microbiology; D002648:Child; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D009503:Neutropenia / Q000209:etiology; D012307:Risk Factors
D000935:Antifungal Agents